To assess whether our patient’s tumor cells’ sensitivity to the EGFR/HER2 inhibitors was due to possible amplification of HER2, additional histopathological analysis including HER2 immunohistochemistry and dual ISH HER2 amplification assay was performed on the lymph node tissue from which the sample cells to the ex vivo assay were isolated. Here, ERBB2 is linked to neoplasm.